{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T23:08:20Z","timestamp":1778454500426,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":19,"publisher":"Springer US","isbn-type":[{"value":"9781071650363","type":"print"},{"value":"9781071650370","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5037-0_14","type":"book-chapter","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:11:56Z","timestamp":1778451116000},"page":"187-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral Blood Mononuclear Cell (PBMC) Humanized Mice as a Platform for a Preclinical In Vivo Evaluation of T-Cell-Dependent Bispecific Antibodies"],"prefix":"10.1007","author":[{"given":"Ryo","family":"Tsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"6012","key":"14_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","volume":"314","author":"UD Staerz","year":"1985","unstructured":"Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314(6012):628\u2013631","journal-title":"Nature"},{"issue":"18","key":"14_CR2","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493\u20132498","journal-title":"J Clin Oncol"},{"issue":"8","key":"14_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"24","key":"14_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387(24):2220\u20132231","journal-title":"N Engl J Med"},{"issue":"10301","key":"14_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet (London, England) 398(10301):665\u2013674","journal-title":"Lancet (London, England)"},{"issue":"24","key":"14_CR6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N\u00a0Engl J Med 387(24):2232\u20132244","journal-title":"N Engl J Med"},{"issue":"16","key":"14_CR7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV et al (2023) Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol 41(16):2893\u20132903","journal-title":"J Clin Oncol"},{"issue":"608","key":"14_CR8","doi-asserted-by":"publisher","first-page":"eabd1524","DOI":"10.1126\/scitranslmed.abd1524","volume":"13","author":"B Belmontes","year":"2021","unstructured":"Belmontes B, Sawant DV, Zhong W et al (2021) Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med 13(608):eabd1524. https:\/\/doi.org\/10.1126\/scitranslmed.abd1524","journal-title":"Sci Transl Med"},{"issue":"2","key":"14_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/bloodadvances.2023010971","volume":"8","author":"L Wang","year":"2024","unstructured":"Wang L, Leach V, Muthusamy N et al (2024) A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment. Blood Adv 8(2):470\u2013481","journal-title":"Blood Adv"},{"issue":"3","key":"14_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO et al (2023) Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol 20(3):192\u2013206","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"14_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2249.2011.04462.x","volume":"166","author":"L Covassin","year":"2011","unstructured":"Covassin L, Laning J, Abdi R et al (2011) Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2r\u03b3(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol 166(2):269\u2013280","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"14_CR12","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1096\/fj.201800636R","volume":"33","author":"MA Brehm","year":"2019","unstructured":"Brehm MA, Kenney LL, Wiles MV et al (2019) Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J 33(3):3137\u20133151","journal-title":"FASEB J"},{"issue":"11","key":"14_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/cmi.2017.106","volume":"15","author":"T Yaguchi","year":"2018","unstructured":"Yaguchi T, Kobayashi A, Inozume T et al (2018) Human PBMC-transferred murine MHC class I\/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol 15(11):953\u2013962","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"14_CR14","doi-asserted-by":"publisher","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","volume":"7","author":"M Kebenko","year":"2018","unstructured":"Kebenko M, Goebeler ME, Wolf M et al (2018) A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors. Oncoimmunology 7(8):e1450710","journal-title":"Oncoimmunology"},{"issue":"2","key":"14_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0300985810378282","volume":"48","author":"O Foreman","year":"2011","unstructured":"Foreman O, Kavirayani AM, Griffey SM et al (2011) Opportunistic bacterial infections in breeding colonies of the NSG mouse strain. Vet Pathol 48(2):495\u2013499","journal-title":"Vet Pathol"},{"key":"14_CR16","volume-title":"Immunodeficient rodents: a guide to their immunobiology, husbandry, and use","author":"NRCUCoIC","year":"1989","unstructured":"NRCUCoIC (1989) Immunodeficient rodents: a guide to their immunobiology, husbandry, and use. National Academy of Sciences, Washington, DC"},{"issue":"2","key":"14_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nri2017","volume":"7","author":"LD Shultz","year":"2007","unstructured":"Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7(2):118\u2013130","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"14_CR18","doi-asserted-by":"publisher","first-page":"12963","DOI":"10.1096\/fj.202001203R","volume":"34","author":"C Ye","year":"2020","unstructured":"Ye C, Yang H, Cheng M et al (2020) A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome. FASEB J 34(9):12963\u201312975","journal-title":"FASEB J"},{"issue":"9","key":"14_CR19","doi-asserted-by":"publisher","first-page":"BSR20211986","DOI":"10.1042\/BSR20211986","volume":"42","author":"A Elhage","year":"2022","unstructured":"Elhage A, Sligar C, Cuthbertson P et al (2022) Insights into mechanisms of graft-versus-host disease through humanised mouse models. Biosci Rep 42(9):BSR20211986. https:\/\/doi.org\/10.1042\/BSR20211986","journal-title":"Biosci Rep"}],"container-title":["Methods in Molecular Biology","Bispecific Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5037-0_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:11:56Z","timestamp":1778451116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5037-0_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650363","9781071650370"],"references-count":19,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5037-0_14","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}